Smith & Nephew ADR had its Relative Strength (RS) Rating upgraded from 79 to 84 Tuesday.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an 80 or higher RS Rating as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
Smith & Nephew ADR is building a cup without handle with a 31.72 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
The company showed -2% earnings growth last quarter. Sales rose 6%.
The company earns the No. 20 rank among its peers in the Medical-Products industry group. Boston Scientific, Axogen and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
